Latest Medtech News
MiMedx has agreed to acquire Sanara MedTech in a cash-and-stock transaction with an enterprise value of approximately $350 million, expanding its presence in the surgical and regenerative medicine markets.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
The acquisition adds Sanara's portfolio of regenerative surgical products and pipeline, including the FDA Breakthrough Device-designated OsStic BioAdhesive Advanced Bone Fixation technology, which is targeted for commercial launch in 2027. The transaction is expected to close by the end of 2026, subject to shareholder and regulatory approvals.
“With Sanara, we will accelerate this effort and meaningfully expand our reach across several subspecialties,” said MiMedx CEO Joseph H. Capper. “On a combined basis, 2027 total revenue is expected to be well in excess of $400 million with an adjusted EBITDA margin expected to be over 20%.”
